Early outcome of Radiofrequency Ablation in treating Hepatocellular carcinoma in risk locations

Doan Thi Kieu Oanh1, Le Van Khang1, Nguyen Thi Thu Thao1, Nguyen Thi Yen1, Nguyen Thi Yen1, Dr Vu Dang Luu
1 Bach Mai Hospital

Main Article Content

Abstract

Background: Radiofrequency ablation is a radical treatment with high efficiency in the very early stages (BCLC 0) and early stages (BCLC A). However, with tumors in risk locations, radiofrequency ablation has many difficulties in determining the tumor on ultrasound and the risk of damage to adjacent organs.


Objectives: To evaluate early outcomes of RFA in treating HCC patients in risk locations.


Subjects and methods: 50 HCC patients in risk locations underwent ablation at the radiology center of Bach Mai hospital. Follow up 3 months to evaluate the effectiveness after the treatment. Results: 50 patients male/female=41/9, average age = 61.63 years old (35–86). 94% patients with HCC have a history of cirrhosis and 88% patients with HCC have a history of hepatitis. Among the tumors in risk locations, the tumors adjacent to the diaphragmatic accounted for the highest rate of 44%. We infused the artificial ascites in 20 cases(40%) and the pleural effusion in 14 cases(28%). Follow-up 3 months after treatment, there was no the major complication. 7 patients had the atelectasis. The rate of tumor complete response was 92%, the rate of tumor incomplete response was 4%. 2 patients appeared new lesions(4%). Conclusion: Radiofrequency ablation is a minimally invasive, safe and effective method for tumors in risk locations.

Article Details

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-693. doi:10.1016/j.jhep.2021.11.018
3. Cao S, Zou Y, Lyu T, et al. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression. Int J Hyperthermia. 2022;39(1):1-7. doi:10.1080/02656736.2021.1998660
4. Knuttinen MG, Van Ha TG, Reilly C, Montag A, Straus C. Unintended thermal injuries from radiofrequency ablation: organ protection with an angioplasty balloon catheter in an animal model. J Clin Imaging Sci. 2014;4:1. doi:10.4103/2156-7514.126018
5. Hsieh YC, Limquiaco JL, Lin CC, Chen WT, Lin SM. Radiofrequency ablation following artificial ascites and pleural effusion creation may improve outcomes for hepatocellular carcinoma in high-risk locations. Abdom Radiol N Y. 2019;44(3):1141-1151. doi:10.1007/s00261-018-1831-6
6. Rungsakulkij N, Suragul W, Mingphruedhi S, Tangtawee P, Muangkaew P, Aeesoa S. Prognostic role of alpha-fetoprotein response after hepatocellular carcinoma resection. World J Clin Cases. 2018;6(6):110-120. doi:10.12998/wjcc.v6.i6.110
7. My L, Lâm N, Thông P. Nghiên cứu hiệu quả bước đầu điều trị ung thư biểu mô tế bào gan bằng đốt sóng cao tần tại khoa chẩn đoán hình ảnh bệnh viện Bạch Mai. Tạp Chí Điện Quang Học Hạt Nhân Việt Nam. 2014;(18):28-33. doi:10.55046/vjrnm.18.373.2014